Neutral evolution in a CMML patient with linear evolution. (A) Inverse mutation allele frequency vs cumulative number of mutations from CMML patient tumors from Merlevede et al.²¹  The R² value was computed as in Johnson et al,¹¹  filtering mutations outside of the frequency range of 0.12 to 0.3. R² > 0.98 was taken as samples compatible with neutral evolution and displayed. (B) Table listing exonic mutations of patient UPN62. This information was extracted from Merlevede et al,²¹  which reports results from whole-genome sequencing of 17 CMML patients. The final column states the impact of the mutation as predicted by Merlevede et al.²¹  (C) Fishplot representing the clonal architecture of the patient with the putative driver mutations (TET2 mutations are present in ∼60% of CMML patients, and mutations in PRRC2B have recently been identified as recurrent in CMML patients²¹ ). Drawn in R using the fishplot library.^99,100  D, damaging mutation; N, neutral mutation; NA, not available.